Centrophenoxine
An older cholinergic/antioxidant drug (a DMAE ester) marketed in some countries for age-related cognitive decline. Human data is mostly old and small; it is popular in anti-ageing nootropic circles.
01 Overview
Centrophenoxine (meclofenoxate) is an ester of DMAE and a chlorophenoxyacetic acid, developed in the 1950s. It has been used clinically in some European and Asian countries for senile dementia and age-related cognitive impairment, and is studied for its reported effect of reducing lipofuscin accumulation in neurons.
Most supporting studies are decades old and modest in size. It is available as a prescription drug in some jurisdictions and sold as a research chemical or supplement elsewhere.
02 Mechanism
Hydrolyses to DMAE, a putative acetylcholine precursor, plus an antioxidant moiety; reported to reduce age-related lipofuscin ('ageing pigment') in brain tissue.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 250–500 mg/day | Oral | |
| Therapeutic | 600–1000 mg/day | Oral | Older trials used up to ~2000 mg/day divided. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Cognitive support in elderlyOlder small trials reported benefit in dementia; healthy-user data is lacking. | Modest | Clinical | |
| Antioxidant / anti-lipofuscin actionReduced lipofuscin accumulation in animal studies. | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Overstimulation and insomniaThe DMAE component can cause restlessness, irritability or insomnia. | Mild | Uncommon | Anecdotal | |
| HeadacheHeadache at higher doses. | Mild | Uncommon | Anecdotal |